Pieris Pharmaceuticals, Inc. General form of registration statement for all companies including face-amount certificate companies

General form of registration statement for all companies including face-amount certificate companies

Cover
- Document And Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Significant Accounting Policies (Policies)
Notes Tables
Notes Details

Note 8 - Income Taxes 1 (Details Textual)

v3.24.4

Note 8 - Income Taxes 1 (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 4,735	$ (4,637)
Domestic Tax Jurisdiction [Member]
Operating Loss Carryforwards	36,700
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	37,600
Pieris Pharmaceuticals, Inc. [Member]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	11,900
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued	0	0
Pieris Pharmaceuticals, Inc. [Member] \| Domestic Tax Jurisdiction [Member]
Operating Loss Carryforwards	43,400
Pieris Pharmaceuticals, Inc. [Member] \| Domestic Tax Jurisdiction [Member] \| Research and Development Tax [Member
Tax Credit Carryforward, Amount	$ 500	300
Pieris Pharmaceuticals, Inc. [Member] \| Domestic Tax Jurisdiction [Member] \| Internal Revenue Service (IRS) [Member]
Open Tax Year	2019 2020 2021 2022 2023
Pieris Pharmaceuticals, Inc. [Member] \| State and Local Jurisdiction [Member]
Operating Loss Carryforwards	$ 46,700
Pieris Pharmaceuticals, Inc. [Member] \| State and Local Jurisdiction [Member] \| Research and Development Tax [Member
Tax Credit Carryforward, Amount	100	$ 100
Pieris Pharmaceuticals, Inc. [Member] \| Foreign Tax Jurisdiction [Member] \| Corporate Income Tax [Member]
Operating Loss Carryforwards	187,600
Pieris Pharmaceuticals, Inc. [Member] \| Foreign Tax Jurisdiction [Member] \| Trade Tax [Member]
Operating Loss Carryforwards	$ 183,700

- Definition

Tax year that remains open to examination under enacted tax laws, in YYYY format.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-15

+ Details

Name:	us-gaap_OpenTaxYear
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:gYearListItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-3

+ Details

Name:	us-gaap_OperatingLossCarryforwards
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.

+ References

+ Details

Name:	us-gaap_TaxCreditCarryforwardAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 217
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-217

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-15

+ Details

Name:	us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-2

+ Details

Name:	us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=pvla_PierisPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TaxCreditCarryforwardAxis=pvla_ResearchAndDevelopmentTaxMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TaxCreditCarryforwardAxis=pvla_CorporateIncomeTaxMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TaxCreditCarryforwardAxis=pvla_TradeTaxMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: